Codebreaker Labs raises $4.5 million seed round for genomic AI platform

Codebreaker Labs closed a $4.5 million seed round led by Kickstart to expand its causal genomics platform and build its first commercial Atlas. The Boulder company plans to use the funding for lab scale-up, scientific hiring and AI tools that help interpret how genetic variants affect human cells.

Why it matters: - Codebreaker Labs is trying to close a core gap in genomics: turning raw DNA sequence data into functional evidence about what specific variants do inside human cells. - The company’s platform is designed to generate data that can improve variant interpretation and strengthen genomic AI models used in research and clinical settings. - The first commercial Atlas is aimed at 2027, giving the company a near-term product path in a field where experimental data remains scarce.

What happened: - Codebreaker Labs announced the close of a $4.5 million seed financing. - Kickstart led the round. - The company is based in Boulder, Colorado. - The financing will support laboratory scale-up, key scientific hires and development of Codebreaker Labs’ first variant Atlases and AI-powered interpretation tools.

The details: - Codebreaker Labs measures how individual single-nucleotide variants affect disease-relevant primary human cells. - The platform is built to generate functional evidence at genome scale for tens of thousands of variants at a time. - The company says the approach helps connect computational predictions with experimental biology. - The first Atlas is being built through a collaboration with a leading children’s hospital. - Initial Atlas work focuses on immunology and blood cancers. - The first commercial Atlas is targeted for 2027. - The first Atlas is designed to measure the effects of 100,000 genomic variants. - Each Atlas will combine curated variant-effect data with AI models trained on that data.

Between the lines: - The funding signals investor interest in companies that pair wet-lab genomics with AI rather than relying on sequence data alone. - Codebreaker Labs is positioning its database as a compounding asset, since each experiment adds to the training set for future models. - Continued backing from existing investors suggests confidence in the company’s technical approach. - New participation from Denver Ventures, Service Provider Capital and Pelican Trust broadens the financing base.

What's next: - Codebreaker Labs plans to use the new capital to expand lab capacity and add scientific talent. - The company will keep building its first commercial Atlas and related interpretation tools. - Academic medical centers, hospitals, genomics institutes, biopharma companies and frontier AI companies can contact hello@codebreakerlabs.io to collaborate. - More information is available on Codebreaker Labs’ website.